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ABSTRACT To evaluate the contribution of the major
histocompatibility complex class I pockets to the binding of
self-peptides recognized by alloreactive cytotoxic T-lymphocyte
(CTL) clones, we have constructed an extensive library of
HLA-A2 mutants with different amino acid substitutions in
each of the six pockets. When these mutants were tested in
cytotoxicity assays with a panel ofHLA-A2-specific afloreactive
CTL clones, each CTL clone showed a unique pattern of
reactivity, implying the different contributions of each pocket
to binding individual peptides. We noted that the majority of
the mutants in pocket B significantly affect recognition by the
CTL clones. Unexpectedly, the mutations influencing allorec-
ognition are found in all other pockets as well. Overall, this
study demonstrates that each ofthe six peptide-binding pockets
plays an important and distinct role in binding of self-peptides
required for recognition of the HLA-A2 molecule by alloreac-
tive CTLs.
Class I major histocompatibility complex molecules are es-
sential for target-cell recognition by alloreactive and antigen-
specific cytotoxic T lymphocytes (CTLs). These molecules
are transported to and expressed on the cell surface as a
trimeric complex composed ofa polymorphic heavy chain, an
invariant 82-microglobulin, and a peptide (1-3). The crystal
structure of the class I protein HLA-A2 (A2) reveals the
presence of an extra electron density, presumably peptides,
in a groove formed by two a-helices of the al and a2
domains, which lie across an eight-stranded l-pleated sheet
floor (4, 5). More recently, a higher resolution analysis of the
A2 structure shows six pockets or subsites, designated
pocket A-F, within the groove (6). Similar structures are also
seen in HLA-Aw68 (7), HLA-B27 (8), and H-2Kb (9). These
pockets contain many of the residues that are polymorphic
among the class I molecules and are proposed to determine
the specificity of peptide interaction.
Sequence analyses of self-peptides purified from different
class I molecules show allele-specific motifs with predomi-
nant amino acids at fixed positions (10, 11). This implies that
peptide binding to the class I molecule is governed by anchor
residues interacting with specific pockets. In the case of
A2-associated peptides, leucine or methionine, commonly
found at position 2, is postulated to fit into pocket B. Previous
studies have used mutant class I molecules to evaluate the
role of these pockets in CTL recognition. However, most
studies tested mutants targeted primarily to pocket B (12-15),
and others examined recognition of peptide-pulsed targets by
virus-specific CTL (16-19). Our study focuses on the con-
tribution of each peptide-binding pocket to alloreactive CTL
recognition. We have constructed an extensive library of A2
mutants with different amino acid substitutions in each of the
six pockets and examined whether these changes affect the
binding of self-peptides as detected by a panel of alloreactive
CTL clones. In contrast to expectation, this study demon-
strates that all six pockets appear to play important but
unique roles in allorecognition of the A2 molecule.
MATERIALS AND METHODS
Construction of Mutant A2 Genes and Their Expression in
HMy2.ClR Cells. Thirty-three mutant A2 genes with single
substitutions in the six peptide-binding pockets of the A2
molecule were constructed by a combination of site-directed
and saturation mutagenesis as described (20, 21). Each of the
mutant genes (listed in Table 1) is designated with the
single-letter code of the original amino acid residue, followed
by the number of the position and the code of the changed
amino acid. The mutant A2 genes were cotransfected with
pSV2-neo into the HLA-A-null human B-lymphoid cell line
HMy2.ClR (C1R) (22) by electroporation. After selection
with Geneticin (G418), the transfectants were analyzed for
their surface A2 expression by flow cytometry (EPICS 7-52)
using indirect immunofluorescence with monoclonal antibod-
ies MA2.1 (23) and BB7.2 (24). Most of the transfectants
showed a single positive peak. The cells expressing double
peaks were sorted by flow cytometry to obtain a single
positive population. The mean logarithm of the fluorescence
intensity (MFI) of each cell line was measured and standard-
ized as the percent relative expression by the following for-
mula: %relativeexpression = [(MFIc1RmutntA2 - MFIc1R-nco)/
(MFkicR wild-type A2 - MFIC1R-neo)] x 100. The expression of
most mutant A2 molecules on the C1R cells was comparable
to that of the wild-type A2 (Table 1). The lowest level of
expression was detected in the W167R mutant at a relative
expression of44%. However, this expression level is sufficient
for CTL recognition since the cell line can be killed effectively
by an A2-specific alloreactive CTL line generated from the
A2-negative donor GK (data not shown). The mutant A2
expression on the C1R cells was monitored prior to use as
targets in cytotoxicity assays.
Establishment of Human A2-Speciflc Alloreactive CTL
Clones. A CTL line specific for the A2 molecule was gener-
ated from peripheral blood lymphocytes of a healthy donor,
DQ (HLA-AI, A33, B8, Bw6, Cw6). The line was stimulated
weekly with COR cells expressing the wild-type A2 molecule
as described (25). After 4 weeks, the DQ line was cloned by
limiting dilution, and eight different CTL clones (DQ-2, -3,
-15, -51, -55, -58, -64, and -72) were obtained. The CTL line
and clones were maintained in RPMI 1640 medium supple-
mented with 10% (vol/vol) fetal calf serum and interleukin 2.
5iCr-Release Cytotoxicity Assay. The CTL clones were
tested for recognition of the mutant A2 molecules in the
standard 5tCr-release assay (26). In each experiment, C1R
cells transfected with the wild-type A2 gene (C1R-A2) and
pSV2-neo gene (ClR-neo) were used as positive and negative
controls, respectively. Specific lysis was calculated as fol-
lows: % specific lysis = [(cpmsample - cpmspontaneous)/
Abbreviations: CTL, cytotoxic T lymphocyte; MFI, mean logarithm
of the fluorescence intensity; E/T, effector to target.
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The mutant genes are designated by the single letter code of the
original amino acid residue at the position of substitution followed by
the number of the position and the code of the changed amino acid
residue.
*The pockets in which the amino acid substitutions are located.
tSurface expression of the A2 mutants on transfected C1R cells was
detected by indirect immunofluorescence and calculated relative to
that of the wild-type molecule.
(Cpmaximum - cpmsPontanOus)] x 100. Spontaneous release
represents the radioactivity released by target cells in the
absence of effectors, and maximum release represents the
radioactivity released by target cells lysed with 5% Triton
X-100.
To allow comparison among different experiments, the
results were standardized as percent relative lysis by the
following formula: % relative lysis = [(% specific lysis of
ClRmutant A2- % specific lysis ofC1Rnem)/(% specific lysis of
ClRwlddtype A2 - % specific lysis of ClRne)] x 100.
RESULTS
Generation of A2-Specific CTL Clones. An A2-reactive
human CTL line was generated from a healthy A2-negative
donor by weekly in vitro stimulation with wild-type A2-
transfected C1R (C1R-A2) cells in the presence of interleukin
2. From this line, eight different clones were isolated by
limiting dilution. These clones were tested for their A2
specificity in the standard 51Cr release assay using C1R-A2
and ClR-neo cells as targets. Fig. 1 shows the cytotoxicity of
two representative clones, DQ-2 and DQ-3, against C1R-A2
and C1R-neo cells at effector to target (E/T) ratios of 0.1-10.
All of the clones lyse the C1R-A2 cells, but fail to kill C1R
target cells not expressing A2. These results demonstrate the
specificity of the CTL clones for the A2 molecule.
To establish peptide specificity of the CTL clones, we
tested the clones for recognition of the peptide-transporter-
deficient cell line T2, which expresses a limited repertoire of
A2-bound self-peptides (27). None of the clones tested here
killed T2 cells, although other CTL clones not used in this
study did (data not shown). This suggests that allorecognition
of the A2 molecule by the CTL clones is peptide-dependent.
Ailoreactive CTL Recognition of Mutant A2 Molecules with
Single Substitutions in the Peptide-Binding Pockets. Eight
CTL clones were tested for reactivity against C1R cells
expressing the mutant A2 molecules. Fig. 2 shows cytotoxic
activities of the DQ-2 and DQ-3 clones against pocket C
mutants an example of the data obtained. The results from
all mutant and CTL clones are summarized and presented as
percent rel tive lysis in Fig. 3. Each ofthe CTL clones shows
a distinct p ttern of reactivity. Some of the clones, particu-
larly DQ-2 and DQ-15, are highly sensitive to many mutations
in all of the ckets. In contrast, the DQ-3 and DQ-64 clones
are tolerant of most of the mutations. Overall, the data
demonstrate that each clone exhibits a different pattern of
mutant recognition, suggesting its unique specificity in rec-
ognizing the A2 molecule. This result is consistent with the
theory that each of the clones may recognize a different
self-peptide bound to the A2 molecule.
Because of the striking predominance of leucine and me-
thionine at position 2 of A2-associated self-peptides (10, 11),
we had expected that alteration ofresidues in pocket B would
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FIG. 1. Specificity ofDQ-2 and DQ-3 clones. Cytotoxic activities
of two representative CTL clones (squares, DQ-2; triangles, DQ-3)
were examined in a standard 51Cr release assay with C1R target cells
expressing the wild-type A2 molecule (closed symbols) and C1R cells
transfected with pSV2-neo (open symbols) at E/T ratios of 0.1-10.
Immunology: Matsui et al.




















































FIG. 2. Recognition of A2 mutants with
substitutions in peptide-binding pocket C by
DQ-2 and DQ-3 clones. Clone DQ-2 (A-C)
and clone DQ-3 (D-F) were tested for rec-
ognition of pocket C mutants F9Y and F9L
(A and D), T731 (B and E), andR97K (C and
F). In each experiment, target cells trans-
fected with the wild-type A2 gene (wt) and
pSV2-neo gene (neo) were included as pos-
itive and negative controls, respectively.
1
E/Is
mutations in other pockets would be less likely to have
widespread effects on all clones. Indeed, we found that
mutations in pocket B have a strong impact on recognition of
alloreactive CTL. Surprisingly, the majority of the mutations
in the other pockets also affect CTL recognition of the A2
molecule. Out of the 33 mutants tested, 29 reduce or abolish
the recognition of at least one of the clones (relative lysis <
50%). One mutation (V152E in pocket E) completely abro-
gates the recognition of all eight clones (relative lysis < 20%o).
When the effect of mutations in the different pockets are
compared, those in pockets A [67%; 48 altered recognition
out of 72 tested (48/72)], B (48%; 46/96), C (66%; 21/32), D
(46%; 26/56), and E (60%; 24/40) have strong impact on most
clones, whereas pocket F mutations appear to have the least
effect (36%; 20/56). This difference is statistically significant
when the pocket F data are compared to the pooled data of
pockets A-E (P < 0.004). However, comparisons between
data of individual pockets show either not significant or
barely significant differences (Table 2). Overall, the results
show that the mutations affecting allorecognition are not
limited to pocket B; rather, they are distributed among all six
pockets. Thus, each of the six pockets has a critical role in
binding self-peptides.
A number of mutations involve residues (7, 9, 66, 97, 99,
114, 147, and 156) of which side chains constitute more than
one peptide-binding pocket and appear to have detrimental
effects on many clones. However, when the data for these
mutants were compared to those of mutants involving single
pockets, we detected no significant difference. Mutations
residing within a single pocket, such as positions 167 and 171
(pocket A), 73 (pocket C), 155 (pocket D), 152 (pocket E), and
146 (pocket F), also have a strong impact on many of the
clones. Again, we noted that these mutations are not clus-
tered to any one pocket. Unexpectedly, we observed that
significant changes at certain invariant residues can be well
tolerated by the CTL clones. This is exemplified by the V25D
substitution, which has a minimal effect on all of the eight
clones. In contrast to this, a relatively conservative change,
phenylalanine to tyrosine at the polymorphic residue 9,
drastically reduced the recognition of many of the clones.
DISCUSSION
To assess the importance of peptide-binding pockets in
allorecognition, we have tested a library of A2 mutants with
amino acid changes in each of the six pockets. With the
exception of mutations at position 113, all of the mutations
tested here involve residues whose side chains are postulated
to contact peptides bound in the groove and not T-cell
receptors (6). We speculate that these mutations alter the
affinity of the A2 molecules for peptides, resulting in pre-
sentation of different peptide repertoires and subsequent loss
of CTL recognition. It seems unlikely that the overall A2
structure is affected drastically by the mutations and/or the
binding of different peptides. In support of this, we observed
no difference in the relative binding of conformation-
sensitive monoclonal antibodies to the mutant A2 molecules
(data not shown). Furthermore, a recent crystallographic
study shows that the overall structures of the A2 and murine
H-2Kb molecules share a high degree of similarity, even
though they bind different sets of peptides and differ in
sequence by 30%6 (9).
Alternatively, the mutations may change the conformation
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can no longer effectively recognize them. The structural
analysis of the murine H-2Kb molecule binding different
peptides suggests some plasticity in the conformation that
both peptide and class I can adopt (9). Thus, it is possible that
the pocket mutations also have subtle effects on the struc-
ture, which can be discriminated by the CTL clones without
altering the peptides bound.
Since leucine or methionine at position 2 of A2-associated
peptides is believed to be the anchor residue interacting with
pocket B (10, 11), we anticipated that mutations in this pocket
would have a strong effect on allorecognition. We were
gratified to note that -50o of the tested pocket B mutants
significantly reduced or abolished allorecognition. These
results are in accord with those of previous work on both A2
(12, 13) and B27 alleles (14, 15). However, we observed that
alterations in other pockets (except F) produce an impact on
recognition equivalent to that of the pocket B mutations. If
this is a general case, it has important implications on the
nature of peptides recognized by alloreactive T cells.
> 50%e
FIG. 3. Allorecognition patterns of
eight CTL clones against mutant A2 mol-
ecules with single substitutions in peptide-
binding pockets A-F. Eight CTL clones
(DQ-2, -3, -15, -51, -55, -58, -64, and -72)
were examined for recognition of the C1R
cells expressing the A2 mutants with
changes in the six peptide-binding pock-
ets. These clones were tested in the stan-
dard 51Cr release assay at an E/T of 1:1.
The results are compared to the specific
lysis of wild-type A2-expressing COR cells
and reported here as percent relative lysis.
The eight CTL clones analyzed in this study were selected
on the basis of their growth properties and not on their
specificity. All of the clones kill C1R cells expressing the
wild-type A2 molecule, but each shows a distinctive recog-
nition pattern of the mutant A2 molecules. These results
suggest that each of the clones represents an alloreactive
CTL recognizing the A2 molecule with a unique specificity.
We also observed that none of the CTL clones recognizes
peptide-transporter-defective T2 cells, which bear very few
A2-associated self-peptides (27). Taken together, these find-
ings are consistent with the theory that the distinct specificity
of the clones in allorecognition may be determined by dif-
ferent self-peptides bound to the A2 molecule.
Sequence analysis of self-peptides isolated from A2 mol-
ecules revealed that A2-associated peptides are 9 amino acids
long with an allele-specific motif consisting of leucine or
methionine at position 2 and valine or leucine at position 9
(10, 11). These residues are suggested to serve as anchor
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Table 2. Statistical significance of the differences in recognition
of the pocket mutants by alloreactive CTLs
A B C D E F
A NS NS NS NS 0.01
B NS NS NS 0.03
C NS NS NS
D - NS NS
E NS
F
Comparisons between the effects of mutations in different pockets
on allorecognition were made by the x2 test (28). To deal with the
problem of multiple comparisons, the P value was multiplied by the
number of tests performed. The same statistical analyses were done
on all mutations pooled and on those affecting only single pockets,
and there was no difference in the values obtained from the two
analyses. NS, not significant (P > 0.05).
ets: position 2 fits into pocket B, while position 9 occupies
pocket F. Thus, such peptides would have been affected most
by changes in these pockets. In accordance with this, Winter
et al. (13) reported the significant effect of mutations within
pocket B on CTL recognition of an A2-restricted influenza
virus matrix peptide. Unexpectedly, our results show that the
mutations altering allorecognition are not limited to a partic-
ular pocket. If these data represent CTL recognition of
self-peptides in general, we speculate that the self-peptides
recognized by alloreactive CTLs may not be characterized by
the known allele-specific motifs and may constitute a rela-
tively minor fraction of the total self-peptides bound to class
I molecules.
Using an extensive library of A2 mutants, we have dem-
onstrated that all six peptide-binding pockets of the A2
molecule play a role in allorecognition. Mutations that can
influence recognition by alloreactive CTL clones are found
not only in pocket B but also in other pockets.
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